GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11 | N/A | 123 | 61 | 5 |
| Inventories | 120 | 94 | 59 | N/A | 92 |
| TOTAL | $131 | $94 | $202 | $73 | $109 |
| Non-Current Assets | |||||
| Intangibles | 23 | 24 | 24 | 15 | 16 |
| TOTAL | $23 | $24 | $24 | $15 | $16 |
| Total Assets | $154 | $118 | $226 | $88 | $125 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,409 | 1,166 | 1,088 | 2,591 | 1,930 |
| Accounts payable and accrued liabilities | 904 | 883 | 878 | 858 | 813 |
| Accrued Expenses | 2,684 | 2,581 | 2,426 | 2,274 | 3,027 |
| Other current liabilities | 3 | 18 | 1,378 | 514 | 514 |
| TOTAL | $5,758 | $5,407 | $6,562 | $6,326 | $6,559 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $5,758 | $5,407 | $6,562 | $6,326 | $6,559 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 591,715 | 591,715 | 591,715 | 457,207 | 364,300 |
| Common Shares | 573 | 573 | 501 | 457 | 364 |
| Retained earnings | -88,804 | -88,498 | -88,966 | -88,205 | -86,805 |
| Other shareholders' equity | -82 | -73 | -87 | -124 | -10 |
| TOTAL | $-5,604 | $-5,289 | $-6,336 | $-6,238 | $-6,434 |
| Total Liabilities And Equity | $154 | $118 | $226 | $88 | $125 |